CN103080122A - 大环内脂的结晶形式及其用途 - Google Patents

大环内脂的结晶形式及其用途 Download PDF

Info

Publication number
CN103080122A
CN103080122A CN2011800174629A CN201180017462A CN103080122A CN 103080122 A CN103080122 A CN 103080122A CN 2011800174629 A CN2011800174629 A CN 2011800174629A CN 201180017462 A CN201180017462 A CN 201180017462A CN 103080122 A CN103080122 A CN 103080122A
Authority
CN
China
Prior art keywords
cem
crystalline form
water
solution
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800174629A
Other languages
English (en)
Chinese (zh)
Inventor
D·E·佩雷拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cempra Pharmaceuticals Inc
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44673574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103080122(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Priority to CN201810569806.0A priority Critical patent/CN108570083A/zh
Publication of CN103080122A publication Critical patent/CN103080122A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2011800174629A 2010-03-22 2011-03-22 大环内脂的结晶形式及其用途 Pending CN103080122A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810569806.0A CN108570083A (zh) 2010-03-22 2011-03-22 大环内脂的结晶形式及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31606310P 2010-03-22 2010-03-22
US61/316,063 2010-03-22
PCT/US2011/029424 WO2011119604A1 (en) 2010-03-22 2011-03-22 Crystalline forms of a macrolide, and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810569806.0A Division CN108570083A (zh) 2010-03-22 2011-03-22 大环内脂的结晶形式及其用途

Publications (1)

Publication Number Publication Date
CN103080122A true CN103080122A (zh) 2013-05-01

Family

ID=44673574

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800174629A Pending CN103080122A (zh) 2010-03-22 2011-03-22 大环内脂的结晶形式及其用途
CN201810569806.0A Pending CN108570083A (zh) 2010-03-22 2011-03-22 大环内脂的结晶形式及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810569806.0A Pending CN108570083A (zh) 2010-03-22 2011-03-22 大环内脂的结晶形式及其用途

Country Status (19)

Country Link
US (4) US8975386B2 (enExample)
EP (2) EP3009442B1 (enExample)
JP (4) JP5711352B2 (enExample)
KR (2) KR20180101643A (enExample)
CN (2) CN103080122A (enExample)
AU (2) AU2011232627B2 (enExample)
BR (1) BR112012023950A2 (enExample)
CA (1) CA2793884C (enExample)
DK (1) DK2550286T3 (enExample)
ES (1) ES2564097T3 (enExample)
HR (1) HRP20160168T1 (enExample)
IL (1) IL222018B (enExample)
MX (1) MX361413B (enExample)
MY (1) MY162411A (enExample)
NZ (1) NZ602544A (enExample)
PL (1) PL2550286T3 (enExample)
RU (1) RU2650883C2 (enExample)
SI (1) SI2550286T1 (enExample)
WO (1) WO2011119604A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104151382A (zh) * 2014-08-08 2014-11-19 广东东阳光药业有限公司 一种固态大环内酯的新晶型
CN104311611A (zh) * 2014-08-13 2015-01-28 广东东阳光药业有限公司 一种制备固态大环内酯的方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2529817C (en) 2003-03-10 2013-02-12 Optimer Pharmaceuticals, Inc. Novel antibacterial agents
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
WO2010048600A1 (en) 2008-10-24 2010-04-29 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
HRP20160168T1 (hr) 2010-03-22 2016-03-25 Cempra Pharmaceuticals Inc Kristalne forme makrolida i njihova uporaba
EP2571506B1 (en) 2010-05-20 2017-05-10 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
EP2968801B1 (en) 2013-03-14 2018-09-26 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
MX356772B (es) 2013-03-15 2018-06-13 Cempra Pharmaceuticals Inc Procesos convergentes para la preparacion de agentes antibacterianos macrolidos.
CN105246334A (zh) 2013-04-04 2016-01-13 哈佛大学的校长及成员们 大环内酯及其制备和使用方法
CN106604729A (zh) * 2014-08-05 2017-04-26 森普拉制药公司 抗菌剂的粉末口服混悬制剂
HK1242920A1 (zh) 2014-10-08 2018-07-06 哈佛大学的校长及成员们 14-元酮内酯及其制备和使用方法
WO2016154591A1 (en) 2015-03-25 2016-09-29 President And Fellows Of Harvard College Macrolides with modified desosamine sugars and uses thereof
JP6112696B1 (ja) * 2015-10-05 2017-04-12 富山化学工業株式会社 ソリスロマイシンを含む錠剤
EP3190122A1 (en) * 2016-01-08 2017-07-12 LEK Pharmaceuticals d.d. A novel synthetic pathway towards solithromycin and purification thereof
WO2018045294A1 (en) * 2016-09-02 2018-03-08 Cempra Pharmaceuticals, Inc. Processes for preparing fluoroketolides
AU2020395150A1 (en) * 2019-12-02 2022-06-23 AliquantumRx, Inc. Salts and polymorphs of cethromycin for the treatment of disease salts and polymorphs of cethromycin

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1354753A (zh) * 1998-11-24 2002-06-19 化学技术研究株式会社 新的中间体,从中制备大环内酯类抗生素试剂的方法
US20060100164A1 (en) * 2003-03-10 2006-05-11 Chang-Hsing Liang Novel antibacterial agents
WO2007059307A2 (en) * 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
WO2009055557A1 (en) * 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
IL114589A (en) 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of erythromycin derivatives
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
EP1291351B1 (en) 1996-09-04 2005-07-13 Abbott Laboratories 6-0 substituted ketolides having antibacterial activity
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
PL337606A1 (en) 1997-06-11 2000-08-28 Pfizer Prod Inc Derivatives of erythromycin 9-oxime
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
AU6484199A (en) 1998-12-10 2000-06-26 Pfizer Products Inc. Carbamate and carbazate ketolide antibiotics
OA11753A (en) 1999-01-27 2005-07-19 Pfizer Prod Inc Ketolide antibiotics.
CA2292359C (en) 1999-01-28 2004-09-28 Pfizer Products Inc. Novel azalides and methods of making same
US6395710B1 (en) 1999-04-16 2002-05-28 Kosan Biosciences, Inc. Macrolide antiinfective agents
CN1373767A (zh) 1999-04-16 2002-10-09 奥索-麦克尼尔药品公司 酮式大环内酯抗菌剂
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
WO2001010878A1 (fr) 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
DE60122791T2 (de) 2000-03-15 2007-10-04 Hanmi Pharm. Co., Ltd. Verfahren zur Herstellung von Clarythromycin mit nicht pharmazeutischer Qualität
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
PT1320355E (pt) 2001-05-18 2006-08-31 Chiron Corp Sistema para administracao de uma formulacao de tobramicina
CA2451391A1 (en) 2001-07-03 2003-01-16 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
AU2003218059A1 (en) 2002-02-22 2003-09-09 Pharmacia Corporation Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
ATE469135T1 (de) 2002-05-30 2010-06-15 Scripps Research Inst Kupferkatalysierte ligierung von aziden und acetylenen
AR043050A1 (es) 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
JP2006524706A (ja) 2003-04-25 2006-11-02 カイロン コーポレイション 新規なケトライド誘導体
US20050014706A1 (en) 2003-07-14 2005-01-20 Kanakeshwari Falzari Method of treating tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
WO2005105821A2 (en) 2004-04-28 2005-11-10 Alembic Limited Process for the preparation of telithromycin
WO2006080954A1 (en) 2004-07-28 2006-08-03 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
CA2591746A1 (en) * 2004-12-21 2006-06-29 Pfizer Products Inc. Macrolides
US20080113926A1 (en) 2005-01-14 2008-05-15 Zrinka Ivezic 9A-Carbamoyl-Y-Aminopropyl- And 9A-Thiocabamoyl-Y-Aminopropyl-Azalides With Antimalarial Activity
WO2007039914A2 (en) 2005-10-06 2007-04-12 Alembic Limited Novel polymorphs of telithromycin
WO2007060627A2 (en) 2005-11-23 2007-05-31 Ranbaxy Laboratories Limited Use of macrolide derivatives for treating acne
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
US7742562B2 (en) * 2007-06-27 2010-06-22 Accuray Incorporated Lower-torso assembly of a treatment couch useable in an X-ray environment
WO2009053259A1 (en) * 2007-10-25 2009-04-30 Sandoz Ag Process for the production of telithromycin
WO2010048600A1 (en) * 2008-10-24 2010-04-29 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
PL2544537T3 (pl) 2010-03-10 2017-10-31 Cempra Pharmaceuticals Inc Pozajelitowe preparaty antybiotyków makrolidowych
HRP20160168T1 (hr) * 2010-03-22 2016-03-25 Cempra Pharmaceuticals Inc Kristalne forme makrolida i njihova uporaba

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1354753A (zh) * 1998-11-24 2002-06-19 化学技术研究株式会社 新的中间体,从中制备大环内酯类抗生素试剂的方法
US20060100164A1 (en) * 2003-03-10 2006-05-11 Chang-Hsing Liang Novel antibacterial agents
WO2007059307A2 (en) * 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
WO2009055557A1 (en) * 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RONALD N.JONES，等: "MIC Quality Control Guidelines and Disk Diffusion Test Optimization for CEM-101,a Novel Fluoroketolide", 《JOURNAL OF CLINICAL MICROBIOLOGY》, vol. 48, no. 4, 30 April 2010 (2010-04-30), pages 1470 - 1473, XP055076239, DOI: doi:10.1128/JCM.01992-09 *
吕扬，等: "《晶型药物》", 31 October 2009, article "晶型药物" *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104151382A (zh) * 2014-08-08 2014-11-19 广东东阳光药业有限公司 一种固态大环内酯的新晶型
CN104311611A (zh) * 2014-08-13 2015-01-28 广东东阳光药业有限公司 一种制备固态大环内酯的方法

Also Published As

Publication number Publication date
KR20130056226A (ko) 2013-05-29
JP2017081953A (ja) 2017-05-18
IL222018B (en) 2019-05-30
US20190040096A1 (en) 2019-02-07
AU2011232627A1 (en) 2012-10-18
RU2012144614A (ru) 2014-04-27
JP2013522367A (ja) 2013-06-13
EP2550286A4 (en) 2013-10-02
US8975386B2 (en) 2015-03-10
US8759500B2 (en) 2014-06-24
HRP20160168T1 (hr) 2016-03-25
MX2012010895A (es) 2013-02-15
KR102006200B1 (ko) 2019-08-01
KR20180101643A (ko) 2018-09-12
MY162411A (en) 2017-06-15
CA2793884A1 (en) 2011-09-29
HK1177937A1 (en) 2013-08-30
AU2016203986A1 (en) 2016-06-30
EP2550286B1 (en) 2015-12-09
EP3009442A1 (en) 2016-04-20
EP3009442B1 (en) 2019-06-19
MX361413B (es) 2018-12-05
RU2650883C2 (ru) 2018-04-18
CN108570083A (zh) 2018-09-25
US20130252915A1 (en) 2013-09-26
NZ602544A (en) 2014-11-28
JP6121387B2 (ja) 2017-04-26
DK2550286T3 (en) 2016-02-29
EP2550286A1 (en) 2013-01-30
SI2550286T1 (sl) 2016-04-29
JP2020002168A (ja) 2020-01-09
WO2011119604A1 (en) 2011-09-29
JP2015063536A (ja) 2015-04-09
CA2793884C (en) 2019-09-10
AU2011232627B2 (en) 2016-03-17
US20160244472A1 (en) 2016-08-25
JP5711352B2 (ja) 2015-04-30
BR112012023950A2 (pt) 2016-07-05
AU2016203986B2 (en) 2016-10-06
US20130018008A1 (en) 2013-01-17
PL2550286T3 (pl) 2016-07-29
ES2564097T3 (es) 2016-03-17

Similar Documents

Publication Publication Date Title
CN103080122A (zh) 大环内脂的结晶形式及其用途
CN102086195B (zh) 达沙替尼多晶型物及其制备方法和药用组合物
US20140079783A1 (en) Pharmaceutical Compositions Comprising Rifaximin and Amino acids, Preparation Methods and Use Thereof
CN101712707A (zh) 罗红霉素三种晶型物质、制法以及药物组合物与用途
CN102453020A (zh) 一种来那度胺的新晶型及其制备方法
PL194752B1 (pl) Krystaliczna postać VI 5,6-dichloro-2-(izopropyloamino)-1-(ß-L-rybofuranozylo)-1H-benzimidazolu, sposób jej wytwarzania, kompozycja farmaceutyczna zawierająca krystaliczną postać i zastosowanie krystalicznej postaci
US8344145B2 (en) Salts of 2-substituted quinolines
HK1182115A (en) Crystalline forms of a macrolide, and uses therefor
HK1221229B (en) Crystalline forms of a macrolide, and uses therefor
HK1221229A1 (en) Crystalline forms of a macrolide, and uses therefor
AU693939B2 (en) Novel crystal forms of 1-(5-methanesulfonamidoindolyl-2- carbonyl)-4-(3-(1-methylethylamino)-2-pyridinyl) piperazine
HK1177937B (en) Crystalline forms of a macrolide, and uses therefor
CN108117570A (zh) 一种替诺福韦艾拉酚胺半富马酸盐的结晶及其制备方法
CN121159545A (en) Baricitinib and isophthalic acid eutectic methylene dichloride solvate and preparation method thereof
CN120383595A (zh) 抑制cdk4/6活性化合物的半l-酒石酸盐一水合物
CN111320589A (zh) 一种非布司他钠盐a晶型及其制备方法和用途
CZ20003709A3 (cs) Nové krystalické formy protivirivé benzimidazolové sloučeniny

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1182115

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20130501

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1182115

Country of ref document: HK